Anti-phospho-GluR1 (Ser831) unphosphorylated blocking peptide

Discontinued Product

Anti-phospho-GluR1 (Ser831) unphosphorylated blocking peptide (Cat. No. 2336) has been withdrawn from sale for commercial reasons.
Description: Blocking peptide (unphosphorylated) for anti-phospho-GluR1 (Ser831) (Cat. No. 2041)
Datasheet
Citations
Reviews
Literature (4)

Biological Activity

Synthetic peptide (LIPQQSINEAI[K]) corresponding to amino acids 826-836 of rat mature GluR1 (Accession No. P19490), with a lysine added to the C-terminus for conjugation. Depletion peptide used during purification of anti-phospho-GluR1 (Ser831) (Cat. No. 2041).

Technical Data

M. Wt 1352.76
Formula C60H104N16O19
Sequence LIPQQSINEAIK
Storage Desiccate at -20°C
Smiles [H]N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCCCN)C(O)=O

The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.

Tocris products are intended for laboratory research use only, unless stated otherwise.

Product Datasheets

Certificate of Analysis is currently unavailable on-line.
Please contact Customer Service

References

References are publications that support the biological activity of the product.

View Related Products by Target

Keywords: Anti-phospho-GluR1 (Ser 831) unphosphoylated blocking peptide, Anti-phospho-GluR1 (Ser 831) unphosphoylated blocking peptide supplier, Blocking, peptides, unphosphorylated, anti-phospho-GluR1, Ser831, Glutamate, AMPA, Receptors, iGluR, Ionotropic, Anti-phospho-GluR1(Ser831), unphosphoylated, blocking, 2336, Tocris Bioscience

Citations for Anti-phospho-GluR1 (Ser831) unphosphorylated blocking peptide

Citations are publications that use Tocris products.

Currently there are no citations for Anti-phospho-GluR1 (Ser831) unphosphorylated blocking peptide.

Reviews for Anti-phospho-GluR1 (Ser831) unphosphorylated blocking peptide

There are currently no reviews for this product. Be the first to review Anti-phospho-GluR1 (Ser831) unphosphorylated blocking peptide and earn rewards!

Have you used Anti-phospho-GluR1 (Ser831) unphosphorylated blocking peptide?

Submit a review and receive an Amazon gift card.

$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image

$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image

$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image

Submit a Review

Literature in this Area

Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* your copy today!

*Please note that Tocris will only send literature to established scientific business / institute addresses.


Addiction Poster

Addiction Poster

The key feature of drug addiction is the inability to stop using a drug despite clear evidence of harm. This poster describes the brain circuits associated with addiction, and provides an overview of the main classes of addictive drugs and the neurotransmitter systems that they target.

Alzheimer's Disease Poster

Alzheimer's Disease Poster

Alzheimer's disease (AD) is a debilitating and progressive neurodegenerative disease and the most common cause of dementia, affecting approximately 30% of individuals aged over 85 years. This poster summarizes the cellular and molecular mechanisms of AD.

Depression Poster

Depression Poster

Major depressive disorder is characterized by depressed mood and a loss of interest and/or pleasure. Updated in 2015 this poster highlights presynaptic and postsynaptic targets for the potential treatment of major depressive disorder, as well as outlining the pharmacology of currently approved antidepressant drugs.

Parkinson's Disease Poster

Parkinson's Disease Poster

Parkinson's disease (PD) causes chronic disability and is the second most common neurodegenerative condition. This poster outlines the neurobiology of the disease, as well as highlighting current therapeutic treatments for symptomatic PD, and emerging therapeutic strategies to delay PD onset and progression.